S011 - Common, Challenging and Controversial Short Topics in Patient Management

Friday, February 16; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

• Manage common yet challenging issues in medical and procedural dermatology
• Identify key perspectives in current and controversial management topics in medical and procedural dermatology

Description

Be a part of this high-yield learning experience in this engaging symposium on common, challenging, and controversial short topics in patient management. Master clinicians from medical and procedural dermatology will speak on a variety of topics affecting adult and pediatric populations. For example, we will discuss topics that include atopic dermatitis, skin cancers, cosmetic dermatology, pediatric dermatology, and psoriasis. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

• Armstrong, April W., MD, MPH: AbbVie – C(H), SP(H); Boehringer Ingelheim – Data Safety Monitoring Board(H); Demira – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding), SP(H); Genzyme Corporation – C(H); Janssen Pharmaceuticals, Inc – SP(H); Janssen-Ortho Inc. – I(Grants/Research Funding); Leo Pharma Inc – C(H), I(Grants/Research Funding); Menlo Therapeutics – C(H); Modernizing Medicine – C(H); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Ortho Dermatologics – C(H); Pfizer Inc. – C(H); Regeneron – I(NC); Regeneron Pharmaceuticals, Inc. – SP(H); Sanofi – I(NC), SP(H); Science 37, Inc. – C(H); UCB – I(Grants/Research Funding);
• Luu, Minnelly, MD: no financial relationships exist with commercial interests.
• Rahman, Zakia, MD: Cutera, Inc. – C(OB); Lumenis – C(OB); Solta Medical Inc – O(EQ); Zeltiq Aesthetics – C(OB);
• Simpson, Eric Lawrence, MD: AbbVie – C(Fees); Eli Lilly and Company – I(Grants/Research Funding); GlaxoSmithKline – C(Fees); Medimmune – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – C(Fees), I(Grants/Research Funding); Regeneron – C(Fees), I(Grants/Research Funding); Roivant Sciences – I(Grants/Research Funding); Tioga Pharmaceuticals, Inc. – I(Grants/Research Funding); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding);
• Wysong, Ashley, MD, MS: Castle Biosciences – I(Grants/Research Funding);